Thetis Pharmaceuticals is advancing the development of TP-317, a first-in-class oral therapy designed to address inflammatory bowel disease (IBD) and solid tumor cancers. TP-317 is a Resolvin E1 (RvE1) drug candidate that operates through the LTB4-BLT1 pathway, which is pivotal in mobilizing the body's innate healing mechanisms. The company’s proprietary HEALER™ technology platform enables the transformation of unstable resolvins into stable, water-soluble compounds, facilitating their clinical application. This innovative approach allows TP-317 to be delivered effectively as an enteric-coated oral tablet, ensuring its release in the upper intestine for optimal absorption into systemic circulation.

The therapeutic potential of TP-317 is underscored by its unique mechanism of action, which promotes immune homeostasis and enhances intestinal barrier function, distinguishing it from existing IBD treatments that often suppress the immune system. In preclinical studies, TP-317 has demonstrated the ability to control inflammation and improve immune responses, making it a promising candidate for treating moderate-to-severe Crohn’s disease and ulcerative colitis. Additionally, in the context of solid tumors, TP-317 has shown efficacy in enhancing antigen presentation, thereby improving anti-tumor immunity. This multi-faceted approach positions TP-317 as a complementary treatment to standard therapies, with potential applications in various cancer types, including colorectal and non-small cell lung cancer.

United States

Thetis Pharmaceuticals is a clinical stage biopharmaceutical company developing a first-in-class, oral Resolvin E1 drug (TP-317) for treating mild-to-moderate inflammatory disorders. The company was founded in 2011 by ex-Pfizer R&D executives and healthcare investors.

Thetis Pharmaceuticals

Company Details